The window of opportunity is shorter than you think

I'm going to Boston this week. And I'm bringing an argument that's going to make some people uncomfortable.

I've been to enough of these conferences to know where the real conversations happen. Not on stage. In the corridor outside the session, where someone catches something you said and wants to pull the thread. Over bad coffee at 7am before the programme starts. In the ten minutes between panels when nobody has anywhere to be yet.

That's what I'm going for. If you're attending Patients as Partners and you work in clinical development, patient strategy, medical affairs, or community engagement, I want to find you. Reply to this email or message me on LinkedIn. I'll be there all week.

The argument I'm bringing: the US clinical research sector is about to face the same reckoning the UK is already inside. Except the US is starting from further behind. And the window is shorter than most teams in the room will want to hear.

Let me be direct about something.

I keep having a version of the same conversation with US clinical development teams. FDA diversity action plans come up. There's a beat. Then someone says: "its not mandatory and we are monitoring it" or "we've got it on the roadmap for next year."

That is the wrong response. And here's why.

The UK is already piloting Inclusion and Diversity Plans, and from April 2026 they become part of the new clinical trials regulatory framework. Right now, UK sponsors and CROs are being asked a question most haven't properly prepared for: did your protocol design give underserved populations a realistic chance of participating?

Not: did you try to recruit diverse patients.

Did your design make participation possible in the first place.

That distinction is where most teams have a gap. And it's the distinction regulators are now trained to look for.

The FDA's Diversity Action Plans, introduced under FDORA 2022 and backed by draft guidance issued in 2024, apply to Phase III and other pivotal trials. The trajectory is not ambiguous. And the infrastructure required to meet these mandates properly, in a way that holds up to scrutiny, takes time to build. Longer than most roadmaps account for.

The UK teams that took this seriously eighteen months ago are ahead. The ones that waited are now retrofitting health equity narratives onto protocols that weren't designed for them. Regulators can see the difference. HTA bodies asking whether trial populations reflect real-world patients can see the difference too.

You have a window of opportunity. I wouldn't assume it stays open.

The more discussions I have about Unwritten Health the more its clear to me that GDPR gets misreprensented. The standard line I hear is that GDPR makes health equity research harder. That collecting demographic data, building community datasets, capturing lived experience at scale, hits legal walls that simply don't exist in the US.

That's partly true. France, Germany, Italy, Spain do not routinely collect census-level ethnicity data. GDPR's classification of ethnicity as special category data means centralised, institutional approaches to diversity data run into a wall fast.

But that wall only stops one kind of model.

Ours was never that model.

Unwritten Health's approach is consent-based and community-driven. Data is gathered from individuals who choose to share it, with full informed consent and community governance. One recognised lawful basis for processing special category data like ethnicity under GDPR is explicit informed consent. That is the basis our model is built on.

So while others are trying to find workarounds for a constraint we've already solved, we're building a dataset that is legally robust across every major European market. That is a structural advantage that cannot be quickly or cheaply replicated.

I'll be making this case at Patients as Partners. If you want to hear the full version, find me.

Download it here: https://download.unwritten.health/en-gb/clinical-trial-recruitment-failure

I wrote it for VP and Director-level clinical research and operations leaders who want to understand exactly where equity risk enters the development lifecycle, what it costs when it's missed, and what decision-grade lived experience data actually looks like in practice.

Practical. Not theoretical. And the fastest way to make the internal case for building this capability before the mandate lands on your desk.

If you're heading to Boston, download it before you get on the plane. Some of what's in it will land differently after this week's conversations.

Download it here: https://download.unwritten.health/en-gb/clinical-trial-recruitment-failure.

Thanks for reading. This newsletter exists because I believe the right framing, in the right hands, changes decisions. If it did that for you this week, even a little, that's enough.

Ashish.